By Anton Ladnyi, CFA · ex-Goldman Sachs · ex-J.P. MorganPublished Updated
NVO — Novo Nordisk at ~$45.57 (down 56% from ATH, down 28% in 52 weeks) on ~13.5x forward P/E reported Q1 2026 EPS $1.04 (+19% vs consensus) but underlying business contracted ~4% CER ex-340B reversal; CagriSema failed non-inferiority vs tirzepatide (Feb 2026); oral Wegovy EMA approved, strong prescription lead vs Foundayo; amycretin is now the key next-gen pipeline.
NVO Price Target & Rating
NVO's quantitative grade is Strong Buy, with significant tail risk (CVaR -45.5%), and quality metrics (net margin 37%, ROE 71%). Novo Nordisk A/S (NVO) trades at $42.81 with a valuation grade of Strong Buy: a trailing P/E of 10.0x at a 54% discount to sector median, net margins of 37.2%, a DCF-implied intrinsic range of $50–$90 suggesting a +63% margin of safety, beta 0.35 (defensive risk profile).
DCF Valuation Range
Key Takeaways
Valuation: Strong Buy grade — P/E 10.0x — DCF range $50–$90 implies +63% margin of safety
Risk: CVaR -45.5% (95th percentile, 1-month) indicates moderate tail exposure; beta of 0.35 amplifies broad market moves in both directions
Strengths: Quality 5.0/5, Size 4.0/5, 37% net margin, 71% ROE dominate the factor profile
Catalyst: U.S. oral semaglutide 25mg FDA decision (Q4 2026); amycretin (zenagamtide) Phase 3 obesity initiation (following Phase 2b data at ADA June 2026); Q3 2026 Wegovy Rx trends showing no share loss to Foundayo
Bear catalyst: Foundayo captures >40% oral GLP-1 U.S. market share by Q1 2027; amycretin Phase 2 signal disappoints; semaglutide U.S. price negotiated below $250/month list equivalent
NVO — Quantitative SnapshotJune 2026
RatingStrong Buy
Price$42.81
Why Strong BuyHigh-quality business at a reasonable valuation with constructive earnings momentum
Main riskElevated tail risk — CVaR -45.5% on a one-month horizon
Tail riskCVaR -45.5% over one month at the 95th percentile
DCF range$50–$90 intrinsic range; margin of safety +63%
Best useCore large-cap Healthcare holding — not a source of diversified sector exposure
Next watchEarnings surprise deceleration trend — monitor next quarter delivery closely
Quantitative Factor Profile
Value
4.5 / 5
Quality
5.0 / 5
Momentum
3.0 / 5
Volatility
5.0 / 5
Size
4.0 / 5
Key Metrics
NVO Key Metrics — Novo Nordisk A/S 2026
Metric
Value
Current Price
$42.81
P/E Ratio (TTM)
10.0x
Forward P/E
12.9x
PEG Ratio
0.19x
P/S Ratio
0.6
EV/EBITDA
1.8
Beta
0.35
Net Margin
37.2%
ROE
71.4%
Debt/Equity
72.1%
Dividend Yield
4.21%
CVaR (95%, 1M)
-45.5%
Market Cap
$189.6B
Analyst View
Anton Ladnyi, CFA · A.L. Capital AdvisoryUpdated 2026-06-11
Rating Rationale
NVO — Novo Nordisk at ~$45.57 (down 56% from ATH, down 28% in 52 weeks) on ~13.5x forward P/E reported Q1 2026 EPS $1.04 (+19% vs consensus) but underlying business contracted ~4% CER ex-340B reversal; CagriSema failed non-inferiority vs tirzepatide (Feb 2026); oral Wegovy EMA approved, strong prescription lead vs Foundayo; amycretin is now the key next-gen pipeline.
Investment Thesis
↑ Bull Case
Oral semaglutide 25mg (oral Wegovy): EMA positive opinion, EU launch H2 2026, U.S. decision Q4 2026; early Rx data showing ~18,400 Rxs/week — vs Foundayo's ~3,700 in comparable period — dominant oral GLP-1 prescription lead
At 13.5x forward P/E vs 5-year historical average 27.9x — implies exceptional mean reversion potential; trading at 19% discount to pharma sector median
Wegovy U.S. market share: 65% of new GLP-1 Rxs despite CagriSema disappointment — injectable franchise remains structurally dominant
Amycretin (zenagamtide, oral GLP-1/amylin co-agonist): Phase 2b results (ADA June 2026) showed 14.6% body weight reduction and -1.71pp A1C in T2D at 36 weeks — advancing to Phase 3; obesity weight loss expected materially higher than T2D data; potential category-defining drug for 2028+ if Phase 3 obesity data confirms superiority
DKK 55B capex building out manufacturing: long-term GLP-1 production capacity investment signals confidence in market size regardless of near-term competition
↓ Bear Case
CagriSema REDEFINE 4 (Feb 2026): failed non-inferiority vs tirzepatide — 23% weight loss but statistically insufficient vs Zepbound; the drug intended to decisively win next-gen obesity war failed
Underlying business contracted ~4% CER in Q1 2026 (adjusted for DKK 26.8B 340B reversal); Ozempic -8% YoY reflects pricing headwinds overwhelming volume
Lilly's Foundayo (oral GLP-1 without food/water restrictions) and retatrutide (triple agonist) represent structural competitive threats to semaglutide-based franchise
Semaglutide LOE in Brazil, Canada, China — generic entry risk in key international markets reduces premium pricing window
GLP-1 price negotiation risk: if MFN or Medicare negotiation sets semaglutide price materially below current, gross margin compression is severe given DKK 55B capex
What Changes the Rating
↑Catalyst:Amycretin Phase 3 obesity data shows >25% weight loss (Phase 2b T2D was 14.6%); U.S. oral semaglutide captures >60% of oral GLP-1 Rxs within 3 months of launch; CagriSema salvage trial succeeds
↓Stop / exit:Foundayo captures >40% oral GLP-1 U.S. market share by Q1 2027; amycretin Phase 2 signal disappoints; semaglutide U.S. price negotiated below $250/month list equivalent
Anton’s personal note
The model points to a strong buy and the DCF math backs it — there is real margin of safety here, which is rare at this stage of the cycle. The DCF gap is striking — the model sees 63% upside, and market consensus is not pricing it. I watch for the catalyst that closes that gap: an earnings beat that resets forward estimates, a sector re-rating, or a margin inflection. Without a visible catalyst, valuation gaps can stay wide longer than logic suggests they should. If the thesis holds across the next two quarters, I would be comfortable carrying this at a meaningful weight. If not — specifically, if margins disappoint or the earnings beat streak breaks — I would reduce before the market fully reprices.
— Anton Ladnyi, CFA
Earnings History
NVO Earnings History — EPS Surprise Rate 2026
Quarter
EPS Est.
EPS Actual
Surprise
Q1 2026
$6.96
$6.63
-4.8% ✗
Q4 2025
$5.90
$6.04
+2.3% ✓
Q3 2025
$4.24
$4.50
+6.0% ✓
Q2 2025
$6.00
$5.96
-0.7% ✗
Quarterly EPS — Estimate vs Actual
Earnings Projections
NVO Forward EPS Consensus Estimates 2026
Quarter
EPS Est.
YoY EPS
Analysts
Q2 2026
$5.20
-12.8%
3
Q3 2026
$4.76
+5.7%
3
Q4 2026
~$4.93
-18.4%
9
Q1 2027
~$5.37
-19.0%
9
~ Estimated from annual consensus — not a direct analyst survey
Hover each scenario for detail · current price $42.81
▼
Bear Case
$28
-34.6%
Fwd P/E: 1.4x
-5.0 revenue CAGR · 10.0 exit multiple
◆
Base Case
$62
+44.8%
Fwd P/E: 3.1x
8.0 revenue CAGR · 16.0 exit multiple
▲
Bull Case
$98
+128.9%
Fwd P/E: 4.8x
18.0 revenue CAGR · 22.0 exit multiple
Pairwise Correlation Matrix
0 of 10 peer pairs correlated above 0.60 — diversification benefit within this cluster is structurally limited.
Extended Analysis — Buy, Hold or Sell? Risk Factors. Portfolio Fit.
Is NVO a buy, hold, or sell?
NVO carries a valuation grade of Strong Buy. At a trailing P/E of 10.0, the stock trades at a 54% discount to the Healthcare sector median of 22.0x. Our discounted cash flow model produces an intrinsic range of $50–$90 — implying a +63% margin of safety at the current price of $42.81. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 6% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter missed by a 4.8% earnings surprise. Analyst estimate revisions are trending downward.
What are NVO's key risk factors?
With a beta of 0.35, NVO exhibits a low-volatility risk profile relative to the broad market. The 95th-percentile CVaR of -45.5% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 4.5% of total portfolio loss in the worst 5% of months. Net margins of 37.2% are significantly above the Healthcare sector average of 18%, reflecting durable pricing power. Return on equity of 71.4% indicates highly efficient capital allocation. The balance sheet is conservatively leveraged at 72% debt-to-equity.
Implied volatility of 3.0% is below realized volatility of 35.9%, potentially making options relatively cheap. Short interest is low at 0.7% of float, suggesting limited bearish conviction.
How does NVO fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — NVO carries a beta of 0.35, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, NVO shows the strongest co-movement with PFE (0.27), LLY (0.18), ABBV (0.17). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The NVO analysis here is a single node in that larger structure.
For the portfolio construction framework underpinning NVO’s position sizing and conviction rating — including IPS guardrails, Black-Litterman allocation, and CVaR constraints — see: Investment Policy Statement Framework →
Investor FAQ
Is NVO a buy or sell in 2026?
Novo Nordisk A/S (NVO) carries a Strong Buy quantitative rating from A.L. Capital Advisory, derived from Discounted Cash Flow intrinsic value analysis, five-factor model scoring (Value, Quality, Momentum, Volatility, Size), and CVaR tail risk measurement. At $42.81, the DCF midpoint margin of safety is +63% (intrinsic value range: $50 bear – $90 bull). Composite factor score: 4.3/5. Strongest factor: Quality (5.0/5). Weakest factor: Momentum (3.0/5). Trailing P/E: 10.0x. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Portfolio Construction Framework →
What is the average analyst target price for NVO?
Wall Street consensus target for NVO: $47.13 (+10.1% upside from the current price of $42.81). The analyst target range spans $39.95 (most bearish) to $63.66 (most bullish). Consensus recommendation: Buy. Note that analyst price targets typically reflect a 12-month forward horizon and are derived from a blend of DCF, comparable-company, and sum-of-the-parts analysis. A.L. Capital Advisory’s quantitative Strong Buy rating is produced independently — from DCF intrinsic value, five-factor model scores, and CVaR tail risk — and does not mechanically track Street consensus. When the two diverge, the divergence itself is informative: it can reflect differences in time horizon, valuation methodology, or the degree to which the current price already discounts the consensus case. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Monte Carlo Simulation Framework →
How does NVO score on Value, Quality, Momentum, Volatility, and Size?
NVO five-factor scores (A.L. Capital Advisory, 1–5 scale): Value 4.5/5 (strong) — measures current price versus DCF intrinsic range and trailing earnings multiples; Quality 5.0/5 (strong) — captures profitability metrics including return on equity, net margin (ROE: 71.4%) and net margin (37.2%); Momentum 3.0/5 (neutral) — reflects recent price trajectory and earnings surprise consistency; Volatility 5.0/5 (strong) — inverse measure derived from beta, where lower historical volatility earns a higher score; Size 4.0/5 (above average) — market capitalisation rank (mega-cap $1T+ scores 5/5). Composite: 4.3/5. Factor scores above 4.0 signal a tailwind in that dimension; below 2.0 signals a material headwind. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Black-Litterman Model →
What is NVO's tail risk and CVaR?
The 95th-percentile Conditional Value at Risk (CVaR) for NVO on a one-month horizon is -45.5%. CVaR represents the expected average loss in the worst 5% of monthly outcomes — a more conservative tail risk measure than standard VaR, which only marks the loss threshold. Beta of 0.35 indicates below-market volatility. For reference, a diversified S&P 500 ETF carries a one-month CVaR of roughly -8% to -12% in normal market conditions; individual equity CVaR is higher due to idiosyncratic risk. At the portfolio level, what matters is the marginal CVaR contribution of each holding — not its standalone figure. The A.L. Capital Advisory Portfolio Health Check quantifies each position's marginal tail-risk contribution across your entire holdings. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: CVaR & Tail-Risk Methodology →
What is NVO's intrinsic value and DCF price target?
A.L. Capital Advisory's DCF model produces an intrinsic value range of $50 (bear case) to $90 (bull case) for Novo Nordisk A/S (NVO). At $42.81, the midpoint margin of safety is +63% (positive = discount to intrinsic mid; negative = premium). The bear-to-bull spread reflects genuine sensitivity to the two dominant DCF inputs: the terminal growth rate and WACC. Terminal value typically accounts for 60-80% of total intrinsic value in most equity DCF models, which is why a range is more analytically sound than a point estimate. The central analytical question is not what the DCF outputs as a single number but which growth trajectory the current market price already discounts. All DCF analysis follows CFA Institute standards and is conducted by Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework →
What would trigger a rating upgrade or downgrade for NVO?
Upgrade trigger: Upgrade to Strong Buy on evidence of accelerating earnings surprise magnitude combined with improvement in the Value factor score — specifically if the current 10.0x P/E is supported by an upward revision to DCF terminal growth assumptions. Downgrade trigger: a sustained reversal in the Quality and Momentum factor scores for two or more consecutive quarters. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Investment Policy Statement Framework →
Does NVO consistently beat earnings estimates?
NVO has beaten consensus EPS estimates in 6% of tracked quarterly periods — indicating inconsistent delivery. The most recent reported quarter missed consensus by 4.8%. Below-average earnings consistency is a primary headwind to the rating and a key watch item in the quantitative model. Earnings surprise magnitude and direction are incorporated into the Momentum and Quality dimensions of the five-factor scoring model. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework →
How does NVO contribute to portfolio risk and diversification?
NVO carries a beta of 0.35 (low-volatility / defensive relative to the broad equity market). A beta above 1.0 means the position amplifies market moves in both directions at a typical portfolio weight. Strongest peer co-movement: PFE (0.27), LLY (0.18), ABBV (0.17). Holding NVO alongside these names in the same portfolio increases concentration risk. True portfolio risk is a function of the full covariance structure — a single stock's beta does not reveal its marginal contribution to portfolio tail loss. The A.L. Capital Advisory Portfolio Health Check quantifies concentration risk (Herfindahl-Hirschman Index), pairwise correlations, and marginal CVaR contribution across all your holdings. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Ledoit-Wolf Covariance Framework →
What quantitative methodology does A.L. Capital Advisory use to analyse NVO?
A.L. Capital Advisory analyses Novo Nordisk A/S (NVO) using a four-component quantitative framework grounded in CFA Institute standards. (1) DCF Valuation: projects free cash flows under bear and bull assumptions, discounts at WACC to produce an intrinsic value range with margin-of-safety calculation. (2) Five-Factor Scoring: each equity is scored 1–5 on Value, Quality, Momentum, Volatility, and Size. (3) CVaR Tail Risk: 95th-percentile Conditional Value at Risk from historical simulation of daily returns on a one-month horizon. (4) Earnings Surprise Analysis: quarterly beat rate and magnitude are incorporated into the Momentum and Quality factor scores. The current Strong Buy rating for NVO is the output of applying this complete framework to current data. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework → · CVaR & Tail-Risk Methodology →
Stress-Test This View Live
Run NVO in Asset Lens
Live DCF valuation, Monte Carlo simulation, options flow intelligence, and full factor decomposition — updated in real time. Free, no account required.
This analysis is produced using a systematic quantitative framework applied to market data and does not constitute investment advice. Prose commentary is AI-assisted and generated from structured quantitative inputs. All data and metrics are as of 2026-06-11 and are point-in-time estimates subject to revision without notice. CVaR figures are based on historical simulation and do not guarantee future outcomes. DCF ranges and upgrade/downgrade triggers are forward-looking statements based on current assumptions and may not materialise. Past performance does not guarantee future results. This analysis does not account for individual circumstances, tax position, or investment objectives — consult a qualified financial advisor before making investment decisions. This content is intended for informational purposes only and does not constitute regulated investment advice under MiFID II or FCA guidelines. This content is not intended for US persons or residents of jurisdictions where its distribution would be contrary to local law or regulation. This service is not directed at residents of Finland, Sweden, Norway, Denmark, Iceland, or Poland. The author may hold long or short positions in securities mentioned in this analysis. Nothing on this page represents a solicitation to buy or sell any security. A.L. Capital Advisory is an independent private advisory practice and is not affiliated with Novo Nordisk A/S.
CFA Portfolio Advisory — NVO
Discuss this analysis, position sizing, or your full portfolio mandate with Anton Ladnyi, CFA.
